{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Novolog&page=3", "query": { "intervention": "Novolog", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 181, "total_pages": 19, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Novolog&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Novolog&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T18:04:05.091Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00071448", "title": "Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "insulin human", "type": "DRUG" }, { "name": "insulin lispro", "type": "DRUG" }, { "name": "insulin aspart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "6 Years to 18 Years" }, "enrollment_count": 378, "start_date": "2002-06", "completion_date": "2004-06", "has_results": false, "last_update_posted_date": "2016-12-22", "last_synced_at": "2026-10-23T18:04:05.091Z", "location_count": 76, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 64 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00071448" }, { "nct_id": "NCT02034513", "title": "A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "insulin degludec", "type": "DRUG" }, { "name": "insulin glargine", "type": "DRUG" }, { "name": "insulin aspart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 501, "start_date": "2014-01-05", "completion_date": "2016-01-11", "has_results": true, "last_update_posted_date": "2019-01-02", "last_synced_at": "2026-10-23T18:04:05.091Z", "location_count": 92, "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Concord, California + 81 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Concord", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02034513" }, { "nct_id": "NCT03874715", "title": "Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "Insulin Aspart SAR341402", "type": "DRUG" }, { "name": "Insulin Aspart", "type": "DRUG" }, { "name": "Insulin glargine U100", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 210, "start_date": "2019-03-11", "completion_date": "2020-07-08", "has_results": true, "last_update_posted_date": "2024-04-17", "last_synced_at": "2026-10-23T18:04:05.091Z", "location_count": 33, "location_summary": "Concord, California • Temecula, California • Ventura, California + 30 more", "locations": [ { "city": "Concord", "state": "California" }, { "city": "Temecula", "state": "California" }, { "city": "Ventura", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Waterbury", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03874715" }, { "nct_id": "NCT00000620", "title": "Action to Control Cardiovascular Risk in Diabetes (ACCORD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atherosclerosis", "Cardiovascular Diseases", "Hypercholesterolemia", "Hypertension", "Diabetes Mellitus, Type 2", "Diabetes Mellitus", "Coronary Disease" ], "interventions": [ { "name": "Anti-hyperglycemic Agents", "type": "DRUG" }, { "name": "Anti-hypertensive Agents", "type": "DRUG" }, { "name": "Blinded fenofibrate or placebo plus simvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "40 Years to 79 Years" }, "enrollment_count": 10251, "start_date": "1999-09", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2016-11-22", "last_synced_at": "2026-10-23T18:04:05.091Z", "location_count": 6, "location_summary": "Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000620" }, { "nct_id": "NCT01848990", "title": "CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "Commercial Hylenex® recombinant (hyaluronidase human injection)", "type": "DRUG" }, { "name": "Precommercial Hylenex recombinant (hyaluronidase human injection)", "type": "DRUG" }, { "name": "Insulin lispro", "type": "DRUG" }, { "name": "Insulin aspart", "type": "DRUG" }, { "name": "Insulin glulisine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Halozyme Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 456, "start_date": "2013-03", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2018-11-07", "last_synced_at": "2026-10-23T18:04:05.091Z", "location_count": 39, "location_summary": "Concord, California • Encino, California • Escondido, California + 35 more", "locations": [ { "city": "Concord", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01848990" }, { "nct_id": "NCT01283425", "title": "Evaluation of the Safety Use of the InsuPatch Device in Daily Life Conditions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "InsuPatch", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Insuline Medical Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 147, "start_date": "2011-02", "completion_date": "2012-04", "has_results": false, "last_update_posted_date": "2014-09-04", "last_synced_at": "2026-10-23T18:04:05.091Z", "location_count": 1, "location_summary": "San Mateo, California", "locations": [ { "city": "San Mateo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01283425" }, { "nct_id": "NCT01023165", "title": "Effects of Intensive Bolus Intravenous Insulin Delivery on Metabolic Integrity in Type 1 and Type 2 Diabetes", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus", "Metabolic Integrity" ], "interventions": [ { "name": "Humulin, Humalog, Novolog", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Global Infusion and Aspiration Systems, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "95 Years", "sex": "ALL", "summary": "18 Years to 95 Years" }, "enrollment_count": 2000, "start_date": "2009-11", "completion_date": "2015-11", "has_results": false, "last_update_posted_date": "2011-06-22", "last_synced_at": "2026-10-23T18:04:05.091Z", "location_count": 1, "location_summary": "Batesville, Mississippi", "locations": [ { "city": "Batesville", "state": "Mississippi" } ], "official_url": "https://clinicaltrials.gov/study/NCT01023165" }, { "nct_id": "NCT00624767", "title": "A Study to Evaluate the Effect of Nasal Insulin on Postprandial Glycemic Control in Type 2 Diabetic Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus" ], "interventions": [ { "name": "Insulin (recombinant human insulin)", "type": "DRUG" }, { "name": "NovoLog", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nastech Pharmaceutical Company, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 18, "start_date": "2008-03", "completion_date": "2008-05", "has_results": false, "last_update_posted_date": "2008-05-20", "last_synced_at": "2026-10-23T18:04:05.091Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00624767" }, { "nct_id": "NCT00428207", "title": "Glycemic Stability of Insulin Aspart Versus Insulin Lispro in Insulin Pump Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "Insulin Aspart versus Insulin Lispro", "type": "DRUG" }, { "name": "Insulin Lispro versus Insulin Aspart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Joslin Diabetes Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 4, "start_date": "2007-02", "completion_date": "2008-08", "has_results": true, "last_update_posted_date": "2017-05-30", "last_synced_at": "2026-10-23T18:04:05.091Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00428207" }, { "nct_id": "NCT01194258", "title": "Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type II" ], "interventions": [ { "name": "Insulin lispro", "type": "DRUG" }, { "name": "Insulin aspart", "type": "DRUG" }, { "name": "Recombinant human hyaluronidase PH20", "type": "DRUG" }, { "name": "Insulin glulisine", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Halozyme Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 132, "start_date": "2010-08", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2014-08-20", "last_synced_at": "2026-10-23T18:04:05.091Z", "location_count": 22, "location_summary": "Concord, California • Encino, California • Escondido, California + 18 more", "locations": [ { "city": "Concord", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "San Mateo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01194258" } ] }